摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3,6-dichloro-1,2,4-benzotriazine 1-oxide | 70373-13-6

中文名称
——
中文别名
——
英文名称
3,6-dichloro-1,2,4-benzotriazine 1-oxide
英文别名
3,6-Dichlorbenzotriazin-1-oxid;3,6-dichloro-benzo[e][1,2,4]triazine 1-oxide;3,6-Dichlorobenzo[e][1,2,4]triazine 1-oxide;3,6-dichloro-1-oxido-1,2,4-benzotriazin-1-ium
3,6-dichloro-1,2,4-benzotriazine 1-oxide化学式
CAS
70373-13-6
化学式
C7H3Cl2N3O
mdl
——
分子量
216.026
InChiKey
BYKLZLPXACLJLY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    13
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    51.2
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3,6-dichloro-1,2,4-benzotriazine 1-oxide 在 palladium on activated charcoal 甲酸铵potassium carbonate 作用下, 以 甲醇丁酮 为溶剂, 反应 6.0h, 生成 methyl 2-{4-[(6-chloro-1,2,4-benzotriazin-3-yl)oxy]phenoxy}propionate
    参考文献:
    名称:
    二。抗肿瘤药2-(4-[(7-氯-2-喹喔啉基)氧基]苯氧基)丙酸(XK469)的一些生物等排体和同类物的合成和生物学评估。
    摘要:
    XK469(1)是我们实验室中评估的最高度和最广泛活性的抗肿瘤药物之一。随后的开发研究导致(R)-(+)1(NSC 698215)进入1期临床试验(NIH UO1-CA62487)。1的抗肿瘤作用机理尚待阐明,这促使人们不断努力拟订1的药效学模式。本研究的重点是对喹喔啉部分中基于拓扑的生物等位替代物进行合成和生物学评估的策略。铅化合物(1)由喹唑啉(4a-d),1,2,4-苯并三嗪(12a-18b)和喹啉(21a-g)环系统合成。对每个1的生物等排体的合成方法都采用了先前工作中开发的方法(请参见ST的Hazeldine; L。的Polin; J。的Kushner; J。的Paluch; J。的White; K.Edelstein; M。的Palomino,E .; TH,Corbett;Horwitz,JP设计,合成和抗肿瘤药2-(4-[(7-氯-2-喹喔啉基)氧基]苯氧基)丙酸(XK469)类似物的生物学评估。J
    DOI:
    10.1021/jm0200097
  • 作为产物:
    描述:
    6-chloro-1,2,4-benzotriazin-3-amine 1-oxide三氟乙酸 、 sodium nitrite 、 三氯氧磷 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 4.0h, 以83%的产率得到3,6-dichloro-1,2,4-benzotriazine 1-oxide
    参考文献:
    名称:
    Pharmacokinetic/Pharmacodynamic Model-Guided Identification of Hypoxia-Selective 1,2,4-Benzotriazine 1,4-Dioxides with Antitumor Activity: The Role of Extravascular Transport
    摘要:
    Pharmacokinetic/pharmacodynamic (PK/PD) modeling has shown the antitumor activity of tirapazamine (TPZ), a bioreductive hypoxia-selective cytotoxin, to be limited by poor penetration through hypoxic tumor tissue. We have prepared a series of 1,2,4-benzotriazine 1,4-dioxide (BTO) analogues of TPZ to improve activity against hypoxic cells by increasing extravascular transport. The 6 substituents modified lipophilicity and rates of hypoxic metabolism. 3-Alkylamino substituents increased aqueous solubility and also influenced lipophilicity and hypoxic metabolism. PK/PD model-guided screening was used to select six BTOs for evaluation against hypoxic cells in HT29 human tumor xenografts. All six BTOs were active in vivo, and two provided greater hypoxic cell killing than TPZ because of improved transport and/or plasma PK. This PK/PD model considers two causes of therapeutic failure (limited tumor penetration and poor plasma pharmacokinetics) often not addressed early in drug development and provides a general strategy for selecting candidates for in vivo evaluation during lead optimization.
    DOI:
    10.1021/jm070670g
点击查看最新优质反应信息

文献信息

  • Benzoazine mono-N-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments
    申请人:Auckland Uniservices Limited
    公开号:EP1468688A2
    公开(公告)日:2004-10-20
    The present invention relates to a synergetistic composition comprising one or more benzoazine-mono-N-oxides, and one or more benzoazine 1,4 dioxides for use in cancer therapy. The invention also provides a range of novel 1,2,4 benzoazine-mono-N-oxides and related analogues. These can be used as potentiators of the cytotoxicity of existing anticancer drugs and therapies for cancer treatment.
    本发明涉及一种协同组合物,包括一种或多种苯并噁唑-单-N-氧化物,以及一种或多种苯并噁唑1,4-二氧化物,用于癌症治疗。 该发明还提供了一系列新颖的1,2,4苯并噁唑-单-N-氧化物及相关类似物。这些可以用作增强现有抗癌药物的细胞毒性和癌症治疗的治疗剂。
  • US4289771A
    申请人:——
    公开号:US4289771A
    公开(公告)日:1981-09-15
  • Pharmacokinetic/Pharmacodynamic Model-Guided Identification of Hypoxia-Selective 1,2,4-Benzotriazine 1,4-Dioxides with Antitumor Activity: The Role of Extravascular Transport
    作者:Michael P. Hay、Kevin O. Hicks、Frederik B. Pruijn、Karin Pchalek、Bronwyn G. Siim、William R. Wilson、William A. Denny
    DOI:10.1021/jm070670g
    日期:2007.12.13
    Pharmacokinetic/pharmacodynamic (PK/PD) modeling has shown the antitumor activity of tirapazamine (TPZ), a bioreductive hypoxia-selective cytotoxin, to be limited by poor penetration through hypoxic tumor tissue. We have prepared a series of 1,2,4-benzotriazine 1,4-dioxide (BTO) analogues of TPZ to improve activity against hypoxic cells by increasing extravascular transport. The 6 substituents modified lipophilicity and rates of hypoxic metabolism. 3-Alkylamino substituents increased aqueous solubility and also influenced lipophilicity and hypoxic metabolism. PK/PD model-guided screening was used to select six BTOs for evaluation against hypoxic cells in HT29 human tumor xenografts. All six BTOs were active in vivo, and two provided greater hypoxic cell killing than TPZ because of improved transport and/or plasma PK. This PK/PD model considers two causes of therapeutic failure (limited tumor penetration and poor plasma pharmacokinetics) often not addressed early in drug development and provides a general strategy for selecting candidates for in vivo evaluation during lead optimization.
  • II. Synthesis and Biological Evaluation of Some Bioisosteres and Congeners of the Antitumor Agent, 2-{4-[(7-Chloro-2-quinoxalinyl)oxy]phenoxy}propionic Acid (XK469)
    作者:Stuart T. Hazeldine、Lisa Polin、Juiwanna Kushner、Kathryn White、Nicole M. Bouregeois、Brianna Crantz、Eduardo Palomino、Thomas H. Corbett、Jerome P. Horwitz
    DOI:10.1021/jm0200097
    日期:2002.7.1
    (21a-g) ring systems. The synthetic approach to each of the bioisosteres of 1 utilized the methodology developed in previous work (see Hazeldine, S. T.; Polin, L.; Kushner, J.; Paluch, J.; White, K.; Edelstein, M.; Palomino, E.; Corbett, T. H.; Horwitz, J. P. Design, Synthesis, and Biological Evaluation of Analogues of the Antitumor Agent 2-(4-[(7-Chloro-2-quinoxalinyl)oxy]phenoxy)propionic acid (XK469)
    XK469(1)是我们实验室中评估的最高度和最广泛活性的抗肿瘤药物之一。随后的开发研究导致(R)-(+)1(NSC 698215)进入1期临床试验(NIH UO1-CA62487)。1的抗肿瘤作用机理尚待阐明,这促使人们不断努力拟订1的药效学模式。本研究的重点是对喹喔啉部分中基于拓扑的生物等位替代物进行合成和生物学评估的策略。铅化合物(1)由喹唑啉(4a-d),1,2,4-苯并三嗪(12a-18b)和喹啉(21a-g)环系统合成。对每个1的生物等排体的合成方法都采用了先前工作中开发的方法(请参见ST的Hazeldine; L。的Polin; J。的Kushner; J。的Paluch; J。的White; K.Edelstein; M。的Palomino,E .; TH,Corbett;Horwitz,JP设计,合成和抗肿瘤药2-(4-[(7-氯-2-喹喔啉基)氧基]苯氧基)丙酸(XK469)类似物的生物学评估。J
查看更多